Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA).

Kim Hørslev-Petersen; Merete Lund Hetland; P. Junker; Jan Pødenphanth; T. Ellingsen; P. Ahlquist; Hanne Merete Lindegaard; A. Linauskas; Annette Schlemmer; M.Y. Dam; I. Hansen; H. C.  Horn; A. Jørgensen; Sophine Boysen Krintel; J. Raun; C. G. Ammizbøll; J.S. Johansen; Mikkel Østergaard; K. Steengaard-Pedersen

Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA).

Kim Hørslev-Petersen, Merete Lund Hetland, P. Junker, Jan Pødenphanth, T. Ellingsen, P. Ahlquist, Hanne Merete Lindegaard, A. Linauskas, Annette Schlemmer, M.Y. Dam, I. Hansen, H. C. Horn, A. Jørgensen, Sophine Boysen Krintel, J. Raun, C. G. Ammizbøll, J.S. Johansen, Mikkel Østergaard, K. Steengaard-Pedersen

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	71
Issue number	3 suppl.
Pages (from-to)	360-1
Number of pages	2
ISSN	0003-4967
Publication status	Published - 2012

Cite this

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphanth, J., Ellingsen, T., Ahlquist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Horn, H. C., Jørgensen, A., Krintel, S. B., Raun, J., Ammizbøll, C. G., Johansen, J. S., Østergaard, M., & Steengaard-Pedersen, K. (2012). Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA). Annals of the Rheumatic Diseases, 71(3 suppl.), 360-1.

Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA). / Hørslev-Petersen, Kim; Hetland, Merete Lund; Junker, P. et al.
In: Annals of the Rheumatic Diseases, Vol. 71, No. 3 suppl., 2012, p. 360-1.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Hørslev-Petersen, K, Hetland, ML, Junker, P, Pødenphanth, J, Ellingsen, T, Ahlquist, P, Lindegaard, HM, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Horn, HC, Jørgensen, A, Krintel, SB, Raun, J, Ammizbøll, CG, Johansen, JS, Østergaard, M & Steengaard-Pedersen, K 2012, 'Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA).', Annals of the Rheumatic Diseases, vol. 71, no. 3 suppl., pp. 360-1.

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphanth J, Ellingsen T, Ahlquist P et al. Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA). Annals of the Rheumatic Diseases. 2012;71(3 suppl.):360-1.

Hørslev-Petersen, Kim ; Hetland, Merete Lund ; Junker, P. et al. / Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA). In: Annals of the Rheumatic Diseases. 2012 ; Vol. 71, No. 3 suppl. pp. 360-1.

@article{98b3ec5abbf8406f82220eb5b8b002e0,

title = "Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA).",

author = "Kim H{\o}rslev-Petersen and Hetland, \{Merete Lund\} and P. Junker and Jan P{\o}denphanth and T. Ellingsen and P. Ahlquist and Lindegaard, \{Hanne Merete\} and A. Linauskas and Annette Schlemmer and M.Y. Dam and I. Hansen and Horn, \{H. C.\} and A. J{\o}rgensen and Krintel, \{Sophine Boysen\} and J. Raun and Ammizb{\o}ll, \{C. G.\} and J.S. Johansen and Mikkel {\O}stergaard and K. Steengaard-Pedersen",

year = "2012",

language = "English",

volume = "71",

pages = "360--1",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "3 suppl.",

}

TY - ABST

T1 - Remisson rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA).

AU - Hørslev-Petersen, Kim

AU - Hetland, Merete Lund

AU - Junker, P.

AU - Pødenphanth, Jan

AU - Ellingsen, T.

AU - Ahlquist, P.

AU - Lindegaard, Hanne Merete

AU - Linauskas, A.

AU - Schlemmer, Annette

AU - Dam, M.Y.

AU - Hansen, I.

AU - Horn, H. C.

AU - Jørgensen, A.

AU - Krintel, Sophine Boysen

AU - Raun, J.

AU - Ammizbøll, C. G.

AU - Johansen, J.S.

AU - Østergaard, Mikkel

AU - Steengaard-Pedersen, K.

PY - 2012

Y1 - 2012

M3 - Conference abstract in journal

SN - 0003-4967

VL - 71

SP - 360

EP - 361

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 3 suppl.

ER -